Deferasirox NDC 69452-159

NDC codes

FDA NDC Directory

Product NDC (as listed)69452-159Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69452-0159Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69452-159-13	69452015913	30 TABLET, FOR SUSPENSION in 1 BOTTLE (69452-159-13)Marketed from Sep 28, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deferasirox
Generic name (nonproprietary): deferasirox
Active ingredients: Deferasirox — 125 mg/1
Dosage form: Tablet, For suspension
Route: Oral
Labeler: Bionpharma Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210920
Marketing start: Sep 28, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 1A2 Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Iron Chelating Activity (Mechanism)
Identifiers: Product ID 69452-159_2f9b625f-3835-4481-e063-6394a90a4bf3SPL ID 2f9b625f-3835-4481-e063-6394a90a4bf3SPL set ID dc690f20-533e-490e-b13d-143382e02351RxCUI 597768, 597770, 597772UNII V8G4MOF2V9UPC 0369452161135
Pharmacologic class: Iron Chelator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469452015913 followed by a unit qualifier and the quantity

Package 69452-0159-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 5, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non‑transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Ov…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210920

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210920
Product	Strength	Form · route	Labeler	Product NDC
Deferasirox	Deferasirox 250 mg/1	Tablet, For suspensionOral	Bionpharma Inc.	69452-160
Deferasirox	Deferasirox 500 mg/1	Tablet, For suspensionOral	Bionpharma Inc.	69452-161